These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22025149)

  • 1. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.
    Pappo AS; Patel SR; Crowley J; Reinke DK; Kuenkele KP; Chawla SP; Toner GC; Maki RG; Meyers PA; Chugh R; Ganjoo KN; Schuetze SM; Juergens H; Leahy MG; Geoerger B; Benjamin RS; Helman LJ; Baker LH
    J Clin Oncol; 2011 Dec; 29(34):4541-7. PubMed ID: 22025149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
    Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
    Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.
    Hyun O J; Luber BS; Leal JP; Wang H; Bolejack V; Schuetze SM; Schwartz LH; Helman LJ; Reinke D; Baker LH; Wahl RL
    J Nucl Med; 2016 May; 57(5):735-40. PubMed ID: 26795289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.
    Juergens H; Daw NC; Geoerger B; Ferrari S; Villarroel M; Aerts I; Whelan J; Dirksen U; Hixon ML; Yin D; Wang T; Green S; Paccagnella L; Gualberto A
    J Clin Oncol; 2011 Dec; 29(34):4534-40. PubMed ID: 22025154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
    Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
    J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
    Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
    Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
    Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
    Malempati S; Weigel B; Ingle AM; Ahern CH; Carroll JM; Roberts CT; Reid JM; Schmechel S; Voss SD; Cho SY; Chen HX; Krailo MD; Adamson PC; Blaney SM
    J Clin Oncol; 2012 Jan; 30(3):256-62. PubMed ID: 22184397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
    Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
    Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?
    Ho AL; Schwartz GK
    J Clin Oncol; 2011 Dec; 29(34):4581-3. PubMed ID: 22025158
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
    Olmos D; Postel-Vinay S; Molife LR; Okuno SH; Schuetze SM; Paccagnella ML; Batzel GN; Yin D; Pritchard-Jones K; Judson I; Worden FP; Gualberto A; Scurr M; de Bono JS; Haluska P
    Lancet Oncol; 2010 Feb; 11(2):129-35. PubMed ID: 20036194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
    BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
    Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
    Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
    Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
    Kurzrock R; Patnaik A; Aisner J; Warren T; Leong S; Benjamin R; Eckhardt SG; Eid JE; Greig G; Habben K; McCarthy CD; Gore L
    Clin Cancer Res; 2010 Apr; 16(8):2458-65. PubMed ID: 20371689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
    Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
    Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.
    Lin EH; Lenz HJ; Saleh MN; Mackenzie MJ; Knost JA; Pathiraja K; Langdon RB; Yao SL; Lu BD
    Cancer Med; 2014 Aug; 3(4):988-97. PubMed ID: 24905030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies for advanced Ewing sarcoma family of tumors.
    Jiang Y; Ludwig J; Janku F
    Cancer Treat Rev; 2015 May; 41(5):391-400. PubMed ID: 25869102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.